Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Brii Biosciences Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners, with each examiner handling 1 case. The prosecution is split across 2 distinct art units.
JADHAO, SAMADHAN JAISING is the busiest examiner with 1 pending action. This reflects the even distribution of the 2 pending office actions between the 2 distinct examiners. Because each action is in a different art unit, the company's 2 pending office actions are being reviewed by different technical specialists. This diversity across 2 distinct art units and 2 distinct examiners suggests that the pending cases involve distinct pharmaceutical or biotechnological subjects.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
| LIU, SUE XU | 1 | 20.9% | +18.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18988667 | ASSESSMENT AND TREATMENT OF CHRONIC HEPATITIS B | JADHAO, SAMADHAN JAISING | 4d overdue |
| 18041948 | PHARMACEUTICAL COMPOSITION CONTAINING NEUROACTIVE STEROID AND USE THEREOF | LIU, SUE XU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18988667 | ASSESSMENT AND TREATMENT OF CHRONIC HEPATITIS B | JADHAO, SAMADHAN JAISING | 4d overdue |
| 18041948 | PHARMACEUTICAL COMPOSITION CONTAINING NEUROACTIVE STEROID AND USE THEREOF | LIU, SUE XU | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18988667 | ASSESSMENT AND TREATMENT OF CHRONIC HEPATITIS B | JADHAO, SAMADHAN JAISING | 1672 | §102§103 | Final Rejection | 4d overdue | Pending | Dec 19, 2024 |
| 18041948 | PHARMACEUTICAL COMPOSITION CONTAINING NEUROACTIVE STEROID AND USE THEREOF | LIU, SUE XU | 1616 | §102§103§112DP | Non-Final OA | — | Pending | Feb 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBrii Biosciences Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Samadhan Jaising Jadhao has the most, with 1 of Brii Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
